SUPPRESSION OF PARATHYROID SECRETION AFTER ADMINISTRATION OF WR‐2721 IN A PATIENT WITH PARATHYROID CARCINOMA
- 1 September 1985
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 23 (3) , 313-318
- https://doi.org/10.1111/j.1365-2265.1985.tb00229.x
Abstract
SUMMARY: WR‐2721 is an organic thiophosphate, known as a radioprotective agent, which also inhibits parathyroid hormone (PTH) secretion and reduces the plasma calcium level in euparathyroid animals and human subjects. In this study we present evidence that WR‐2721 is also able to reduce an abnormal PTH secretion in a case of parathyroid carcinoma. The intravenous infusion of a single dose (750 mg/m2) of WR‐2721 was followed within 3 h by a reduction in the plasma concentration of PTH by 60%, and of Ca by about 0·45 mmol/l. These changes were associated with a diminution in urinary cAMP excretion. Based on this observation it appears that WR‐2721 merits further investigation as a possible agent for the medical treatment of hyperparathyroidism.This publication has 4 references indexed in Scilit:
- Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)New England Journal of Medicine, 1983
- Calcium-dependent, parathyroid hormone-independent regulation of 1,25-dihydroxyvitamin DAmerican Journal of Physiology-Endocrinology and Metabolism, 1980
- A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasmaArchives of Biochemistry and Biophysics, 1976
- RELATION BETWEEN SERUM AND URINARY CALCIUM WITH PARTICULAR REFERENCE TO PARATHYROID ACTIVITYThe Lancet, 1969